Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma
Nyall R. London, Dara Bracken-Clarke, Elisabetta Xue, Isaac Brownell, Wojciech K. Mydlarz, Evrim B. Turkbey, Lisa M. Cordes, Jennifer L. Marté, Lisa M. Rooper, Shrey B. Shah, Michell Manu, Zoukaa B. Sargi, James L. Gulley, Charalampos S. Floudas · 2026
Read Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma by Nyall R. London, Dara Bracken-Clarke, Elisabetta Xue, Isaac Brownell, Wojciech K. Mydlarz, Evrim B. Turkbey, Lisa M. Cordes, Jennifer L. Marté, Lisa M. Rooper, Shrey B. Shah, Michell Manu, Zoukaa B. Sargi, James L. Gulley, Charalampos S. Floudas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13522318.txt.
Description
Nyall R. London leads a 2026 first immunotherapy trial in recurrent or spread olfactory neuroblastoma, a rare nose tumour with no established treatment at that stage. Eleven patients received a dual-action fusion drug that traps a growth signal while blocking the PD-L1 checkpoint, dosed every two weeks.
Enrolment stopped early when drug development was discontinued. No tumours shrank objectively, so the main goal was missed. Half of evaluable first-cohort patients held stable disease, some durably, with one showing complete metabolic clearance on specialised imaging. Severe drug-linked harms affected three patients, including immune diabetes and bleeding events. Longer stable control hints at benefit for a subset.
Catalog record
| CREATOR | Nyall R. London, Dara Bracken-Clarke, Elisabetta Xue, Isaac Brownell, Wojciech K. Mydlarz, Evrim B. Turkbey, Lisa M. Cordes, Jennifer L. Marté, Lisa M. Rooper, Shrey B. Shah, Michell Manu, Zoukaa B. Sargi, James L. Gulley, Charalampos S. Floudas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32714 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |